

JUL 22 2003 4:54PM

FISH&RICHARDSON_617-542-8906

NO. 9032 P. 3

Applicant : Zheng Xin Dong
Serial No. : 09/857,636
Filed : June 7, 2001
Page : 2 of 4

Attorney's Docket No.: 00537-186002 / BPC089/WO

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 to 9 (Cancelled).

10. (Currently amended) A compound ~~according to claim 9~~ wherein said compound is
[Aib^{8,35}]hGLP-1(7-36)NH₂ (SEQ ID NO:2),
[Aib⁸, β-Ala³⁵]hGLP-1(7-36)NH₂ (SEQ ID NO:5),
[Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO:7),
[Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl)]hGLP-1(7-38)NH₂ (SEQ ID NO:8),
[Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO:9), or
[Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), β-Ala³⁷]hGLP-1(7-37)-OH (SEQ ID NO:14), or a
pharmaceutically acceptable salt thereof.

11. (Currently Amended) A pharmaceutical composition comprising an effective
amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof and
a pharmaceutically acceptable carrier or diluent.

12. (Currently Amended) A method of eliciting an agonist effect from a GLP-1
receptor in a subject in need thereof which comprises administering to said subject an effective
amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof.

JUL. 22. 2003 4:54PM

FISH&RICHARDSON_617-542-8906

Applicant : Zheng Xin Dong
Serial No. : 09/857,636
Filed * : June 7, 2001
Page : 3 of 4

Attorney's Docket No.: 00537-186002 / BPC089/WO

13. (Currently Amended) A method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof.

14. (Original) A method according to claim 13 wherein said disease is Type I diabetes or Type II diabetes.

Claims 15-18 (Cancelled).